Iron chelator-based amplification strategy for improved targeting of transferrin receptor with SPIO

Cancer Biology and Therapy

Volumn 7, Issue 6, 2008, Pages 889-895

  Zhang, Clare Y ^a   Lu, Jing ^b   Tsourkas, Andrew ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD71; Iron oxide; Magnetic resonance; Molecular imaging; Nanoparticle; SPIO; Transferrin

Indexed keywords

DEFEROXAMINE; IRON CHELATING AGENT; IRON OXIDE; NANOPARTICLE; TRANSFERRIN RECEPTOR; CD71 ANTIGEN; CHELATING AGENT; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; IRON; LEUKOCYTE ANTIGEN; METAL NANOPARTICLE;

ARTICLE; CANCER DIAGNOSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; TEMPERATURE SENSITIVITY; UPREGULATION; BIOSYNTHESIS; CELL STRAIN K 562; CHEMISTRY; DOSE RESPONSE; GENE EXPRESSION REGULATION; INSTRUMENTATION; MAGNETISM; METABOLISM; METHODOLOGY; NEOPLASM;

ANTIGENS, CD; CHELATING AGENTS; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FERRIC COMPOUNDS; GENE EXPRESSION REGULATION; HUMANS; IRON; K562 CELLS; MAGNETIC RESONANCE IMAGING; MAGNETICS; METAL NANOPARTICLES; NEOPLASMS; RECEPTORS, TRANSFERRIN;

EID: 46749144101     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.6.5893     Document Type: Article

References (33)

1. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006; 121:144-58.
2. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002; 54:561-87.
3. Hogemann Savellano D, Bos E, Blondet C, Sato F, Abe T, Josephson L, Weissleder R, Gaudet J, Sgroi D, Peters PJ, Basilion JP. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003; 5:495-506.
4. Walker RA, Day SJ. Transferrin receptor expression in non-malignant and malignant human breast tissue. J Pathol 1986; 148:217-24.
5. Tonik SE, Shindelman JE, Sussman HH. Transferrin receptor is inversely correlated with estrogen receptor in breast cancer. Breast Cancer Res Treat 1986; 7:71-6.
6. Keer HN, Kozlowski JM, Tsai YC, Lee C, McEwan RN, Grayhack JT. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol 1990; 143:381-5.
7. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol 1993; 156:212-7.
8. Hoyes KP, Hider RC, Porter JB. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res 1992; 52:4591-9.
9. Barankiewicz J, Cohen A. Impairment of nucleotide metabolism by iron-chelating deferoxamine. Biochem Pharmacol 1987; 36:2343-7.
10. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006; 121:159-76.
11. Vavere AL, Welch MJ. Preparation, biodistribution, and small animal PET of 45Ti-transferrin. J Nucl Med 2005; 46:683-90.
12. Smith TA, Perkins AC, Walton PH. 99mTc-labelled human serum transferrin for tumour imaging: an in vitro and in vivo study of the complex. Nucl Med Commun 2004; 25:387-91.
13. Weiner RE. The mechanism of 67Ga localization in malignant disease. Nucl Med Biol 1996; 23:745-51.
14. Becker A, Riefke B, Ebert B, Sukowski U, Rinneberg H, Semmler W, Licha K. Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin. Photochem Photobiol 2000; 72:234-41.
15. Shan L, Wang S, Sridhar R, Bhujwalla ZM, Wang PC. Dual probe with fluorescent and magnetic properties for imaging solid tumor xenografts. Mol Imaging 2007; 6:85-95.
16. Pirollo KF, Dagata J, Wang P, Freedman M, Vladar A, Fricke S, Ileva L, Zhou Q, Chang EH. A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol Imaging 2006; 5:41-52.
17. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med 1998; 40:236-42.
18. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49:403-8.
19. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000; 6:351-5.
20. Moore A, Basilion JP, Chiocca EA, Weissleder R. Measuring transferrin receptor gene expression by NMR imaging. Biochim Biophys Acta 1998; 1402:239-49.
21. Moore A, Josephson L, Bhorade RM, Basilion JP, Weissleder R. Human transferrin receptor gene as a marker gene for MR imaging. Radiology 2001; 221:244-50.
22. Ichikawa T, Hogemann D, Saeki Y, Tyminski E, Terada K, Weissleder R, Chiocca EA, Basilion JP. MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia 2002; 4:523-30.
23. Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem 2000; 11:941-6.
24. Le NT, Richardson DR. Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation. Carcinogenesis 2003; 24:1045-58.
25. Kelly KA, Allport JR, Tsourkas A, Shinde Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res 2005; 96:327-36.
26. Bridges KR, Cudkowicz A. Effect of iron chelators on the transferrin receptor in K562 cells. J Biol Chem 1984; 259:12970-7.
27. Lee JH, Engler JA, Collawn JF, Moore BA. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 2001; 268:2004-12.
28. Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 2002; 22:225-50.
29. Hildebrandt IJ, Iyer M, Wagner E, Gambhir SS. Optical imaging of transferrin targeted PEI/DNA complexes in living subjects. Gene Ther 2003; 10:758-64.
30. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983; 36:539-45.
31. Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 1999; 31:1111-37.
32. Richardson DR. Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 1997; 75:1164-80.
33. Dayani PN, Bishop MC, Black K, Zeltzer PM. Desferoxamine (DFO) - mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 2004; 67:367-77.